Ignyta, Inc. (RXDX) Shares Sold by Nexthera Capital LP
Nexthera Capital LP reduced its stake in shares of Ignyta, Inc. (NASDAQ:RXDX) by 25.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,000 shares of the biopharmaceutical company’s stock after selling 85,000 shares during the quarter. Ignyta comprises approximately 1.1% of Nexthera Capital LP’s portfolio, making the stock its 21st largest holding. Nexthera Capital LP owned about 0.44% of Ignyta worth $2,588,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors also recently made changes to their positions in the stock. Victory Capital Management Inc. raised its stake in Ignyta by 29.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,638,632 shares of the biopharmaceutical company’s stock worth $37,660,000 after acquiring an additional 833,798 shares in the last quarter. Broadfin Capital LLC raised its stake in Ignyta by 16.9% during the 1st quarter. Broadfin Capital LLC now owns 2,637,346 shares of the biopharmaceutical company’s stock worth $22,681,000 after acquiring an additional 380,800 shares in the last quarter. Vanguard Group Inc. raised its stake in Ignyta by 44.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,776,484 shares of the biopharmaceutical company’s stock worth $18,387,000 after acquiring an additional 548,307 shares in the last quarter. Emerald Advisers Inc. PA acquired a new stake in Ignyta during the 2nd quarter worth $16,905,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in Ignyta during the 2nd quarter worth $12,018,000. Hedge funds and other institutional investors own 80.82% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Ignyta, Inc. (RXDX) Shares Sold by Nexthera Capital LP” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/ignyta-inc-rxdx-shares-sold-by-nexthera-capital-lp/1610809.html.
Several equities research analysts recently commented on RXDX shares. ValuEngine upgraded shares of Ignyta from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Jefferies Group LLC reissued a “buy” rating and set a $27.00 price objective on shares of Ignyta in a research report on Thursday, June 22nd. Zacks Investment Research downgraded shares of Ignyta from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Cantor Fitzgerald set a $15.00 price objective on shares of Ignyta and gave the stock a “buy” rating in a research report on Monday, July 10th. Finally, BidaskClub downgraded shares of Ignyta from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Ignyta has a consensus rating of “Hold” and an average price target of $21.00.
Shares of Ignyta, Inc. (RXDX) traded up 2.28% on Thursday, reaching $13.45. 510,521 shares of the company’s stock traded hands. The stock’s market capitalization is $756.60 million. Ignyta, Inc. has a 52 week low of $4.15 and a 52 week high of $13.60. The company has a 50 day moving average of $11.10 and a 200-day moving average of $9.26.
Ignyta (NASDAQ:RXDX) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.07. Equities research analysts forecast that Ignyta, Inc. will post ($2.57) earnings per share for the current year.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Receive News & Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.